RFA-NS-23-027: Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 8, 2024.
From the official notice on Grants.gov, last changed May 15, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeRM1
- Clinical trialsOptional
- Funded byNINDS
- Median yearly award$2.1 million
- Typical project length5 years
- RM1, Research Project with Complex Structure. A large research project with several connected parts under one award. Other open RM1 notices.
Projects funded under RFA-NS-23-027 were run by National Institute of Neurological Disorders and Stroke (NINDS, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
This notice replaced RFA-NS-22-011.
Application due dates, page limits and budget limits are set in the notice. Read RFA-NS-23-027 in the NIH Guide.
Key dates
| Posted | May 15, 2023 |
|---|---|
| Deadline | October 8, 2024 |
| Archived by Grants.gov | November 13, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Reissue of RFA-NS-22-011 to comply with DMSP changes. No changes to receipt dates or locus of review. This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. This program is distinct from the NINDS P01 in that it will support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams are encouraged to consider transformative objectives with defined 5-year outcomes.
Funded under RFA-NS-23-027 so far
NIH funded 5 projects under RFA-NS-23-027 in fiscal 2025 to 2026, at 3 institutions. The median yearly award was $2.1 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Clinical discovery and validation of delivery vectors to empower cures for CNS diseases | University of California, San Francisco | 2026 | $2.7 million |
| CRISPR/dCas9-Targeted Histone Demethylation Interplays with DNA Repair to Contract GAA Repeats in Friedreich's Ataxia | Florida International University | 2026 | $1.3 million |
| DECIPHERING THE MOLECULAR BASIS OF SOMATIC GAA-REPEAT DYNAMICS IN SCA27B | University of Miami School of Medicine | 2026 | $1.8 million |
| Molecular determinants and consequences of disease-specific tau conformers in neurons and glia | University of California, San Francisco | 2026 | $2.4 million |
| Antigen-directed therapies for autoantibody associated neuroinflammatory diseases. | University of California, San Francisco | 2026 | $2.1 million |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-NS-23-027 still open?
No. It closed on October 8, 2024.
Who can apply for Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional)?
Closed October 8, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-NS-23-027?
NIH RePORTER lists 5 projects funded under RFA-NS-23-027 in fiscal 2025 to 2026, at 3 institutions. The most were at University of California, San Francisco, Florida International University, University of Miami School of Medicine.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)
- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
- Somatic Mosaicism across Human Tissues (SMaHT) Program: Experimental and Computational Technology Development (RM1 Clinical Trial Not Allowed)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- R3PEATS Multi-Team Triangulation: Collaborative Cross-Method Approaches to Scientific Discovery (RM1)
- BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed)